A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Inclusion Criteria: * Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus. * Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis. * Able to tolerate topical corticosteroids for atopic dermatitis lesions. Exclusion Criteria: * Prior exposure to any Janus kinase (JAK) inhibitor. * Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study. * Requirement of prohibited medications during the study. * Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.